All projects in this SPORE will use human specimens for translational research directed at reducing theincidence and mortality of pancreatic cancer. In order to provide the necessary specimens, a PancreasTumor SPORE Tissue Bank has been developed in cooperation with and under the auspices of theUniversity of Nebraska Medical Center (UNMC) Tumor Bank. There are two components to this resource.The first component is a conventional tissue bank, which captures and stores all excess surgical materialfrom patients seen at UNMC and affiliated institutions, related to pancreatic and Gl malignancies. Thistissue bank also captures and stores samples related to clinical trials that are ongoing as part of SPOREactivites. The second component is an organ harvest/rapid autopsy program in which patients who die withpancreatic cancer donate their organs for research purposes. This program captures and processes entireinternal organs from these patients, including all available samples of primary tumor and metastases.Theguidelines and protocols for collecting specimens established by the UNMC Tumor Bank and the InstitutionalReview Board are followed for the SPORE proposal. This core facility stores normal, benign (i.e. acuteand/or chronic fibrosing pancreatitis) and malignant pancreatic tissues (including both primary and metastaticpancreatic carcinomas) and peripheral blood lymphocytes, plasma and serum from patients with pancreaticmalignancies. The Bank also coordinates collection and storage of pancreatic ductal secretions andperitoneal washings. Cytogenetic analysis is performed on malignant lesions when possible. The coreincludes a mechanism for database management and specimen distribution. A uniform system ofprioritization of requested materials has been defined and used by the Pancreas Tumor SPORE Tissue BankOversight Committee. This core facility is intended to benefit the specific research activities of the SPORE,as well as the research activities of other scientists within and outside of UNMC who are concentrating ontranslational research issues. Additionally, tissues are available for distribution through NCI supported tissuenetworks in national prioritization. Only specimens obtained from clinically indicated surgeries after all otherdiagnostic procedures have been performed are submitted to the Pancreas Tumor SPORE Tissue Bank fortranslational research. The specimens would otherwise be discarded or disposed of. Eligible patients havethe opportunity to participate by submitting written informed consent. There is no risk to the patient orcompromise to the patient's care, since all of the procedures performed would be performed for diagnosticreasons regardless of the SPORE. Members of the pathology department and the clinical departments areparticipants in the individual research projects and thus, also contribute to the Core for maximal and effectiveaccumulation of satisfactory specimens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA127297-01A2
Application #
7507419
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-07-01
Project End
2013-06-30
Budget Start
2008-07-01
Budget End
2009-08-31
Support Year
1
Fiscal Year
2008
Total Cost
$67,795
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Nimmakayala, Rama Krishna; Batra, Surinder K; Ponnusamy, Moorthy P (2018) Unraveling the journey of cancer stem cells from origin to metastasis. Biochim Biophys Acta Rev Cancer 1871:50-63
Aithal, Abhijit; Rauth, Sanchita; Kshirsagar, Prakash et al. (2018) MUC16 as a novel target for cancer therapy. Expert Opin Ther Targets 22:675-686
Barkeer, Srikanth; Chugh, Seema; Batra, Surinder K et al. (2018) Glycosylation of Cancer Stem Cells: Function in Stemness, Tumorigenesis, and Metastasis. Neoplasia 20:813-825
Naramura, Mayumi; Natarajan, Amarnath (2018) Mouse Pancreatic Tumor Model Independent of Tumor Suppressor Gene Inactivation. Pancreas 47:e27-e29
Contreras, Jacob I; Robb, Caroline M; King, Hannah M et al. (2018) Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. ACS Chem Biol 13:1148-1152
Wang, Gang; Biswas, Anup K; Ma, Wanchao et al. (2018) Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat Med 24:770-781
Murthy, Divya; Attri, Kuldeep S; Singh, Pankaj K (2018) Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Front Physiol 9:335
Barkeer, Srikanth; Chugh, Seema; Karmakar, Saswati et al. (2018) Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells. BMC Cancer 18:1157
Rana, Sandeep; Sonawane, Yogesh A; Taylor, Margaret A et al. (2018) Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy. Bioorg Med Chem Lett 28:3736-3740
Roy, Sohini; Bag, Arup K; Dutta, Samikshan et al. (2018) Macrophage-Derived Neuropilin-2 Exhibits Novel Tumor-Promoting Functions. Cancer Res 78:5600-5617

Showing the most recent 10 out of 191 publications